Abstract
Expanded activated autologous lymphocyte (EAAL) therapy with CD3(+)CD8(+) cytotoxic T lymphocyte and CD3(-)56(+) natural killer cell as the major effector cells is a type of adoptive cell therapy. In this study, 19 patients with metastatic tumors received EAAL therapy. Two to four weeks after the administration of EAAL cells, the subsets of CD3(+)CD8(+) T lymphocytes and CD3(-)CD56(+) natural killer cells in the peripheral blood were increased significantly in comparison with those before the therapy. The number of IFN-γ secreting cells also significantly increased after the EAAL infusion (p=0.002) and the p values for the counts of CD3(+)IFN-γ(+) lymphocytes and CD3(-)IFN-γ(+) lymphocytes were 0.006 and 0.015, respectively. Moreover, the percentage of IFN-γ producing cells of the CD3(+), CD8(+) and CD3(-) subsets after infusion were all increased significantly, which indicated that EAAL therapy was able to enrich the potentially anti-tumor cytotoxic peripheral blood lymphocytes.
Copyright © 2010. Published by Elsevier Inc.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antigens, CD / immunology
-
Antigens, CD / metabolism
-
Blood Transfusion, Autologous / adverse effects
-
Blood Transfusion, Autologous / methods
-
Breast Neoplasms / immunology
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology
-
Breast Neoplasms / therapy
-
Carcinoma, Non-Small-Cell Lung / immunology
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Carcinoma, Non-Small-Cell Lung / therapy
-
Colonic Neoplasms / immunology
-
Colonic Neoplasms / mortality
-
Colonic Neoplasms / pathology
-
Colonic Neoplasms / therapy
-
Cytokine-Induced Killer Cells / cytology
-
Cytokine-Induced Killer Cells / metabolism
-
Cytokine-Induced Killer Cells / transplantation*
-
Disease-Free Survival
-
Female
-
Humans
-
Immunotherapy, Adoptive / adverse effects*
-
Immunotherapy, Adoptive / methods*
-
Interferon-gamma / immunology
-
Interferon-gamma / metabolism
-
Interleukin-10 / blood
-
Interleukin-10 / immunology
-
Killer Cells, Natural / cytology
-
Killer Cells, Natural / immunology
-
Killer Cells, Natural / metabolism
-
Killer Cells, Natural / transplantation
-
Leukocytes, Mononuclear / cytology
-
Leukocytes, Mononuclear / immunology
-
Lung Neoplasms / immunology
-
Lung Neoplasms / mortality
-
Lung Neoplasms / pathology
-
Lung Neoplasms / therapy
-
Lymphocyte Count
-
Male
-
Middle Aged
-
Neoplasm Metastasis / therapy
-
Neoplasm Staging
-
Neoplasms / immunology*
-
Neoplasms / mortality
-
Neoplasms / pathology
-
Neoplasms / therapy*
-
Small Cell Lung Carcinoma / immunology
-
Small Cell Lung Carcinoma / mortality
-
Small Cell Lung Carcinoma / pathology
-
Small Cell Lung Carcinoma / therapy
-
Survival Analysis
-
T-Lymphocyte Subsets / cytology
-
T-Lymphocyte Subsets / immunology
-
T-Lymphocyte Subsets / metabolism
-
T-Lymphocyte Subsets / transplantation
-
Treatment Outcome
Substances
-
Antigens, CD
-
IL10 protein, human
-
Interleukin-10
-
Interferon-gamma